Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
NuCana plc is a biotechnology business based in the US. NuCana shares (NCNA) are listed on the NASDAQ and all prices are listed in US Dollars. NuCana employs 29 staff and has a market cap (total outstanding shares value) of USD$246.3 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced investors
52-week range | USD$4.04 - USD$9.75 |
---|---|
50-day moving average | USD$5.9832 |
200-day moving average | USD$5.2102 |
Wall St. target price | USD$1155.19 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-0.634 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Gross profit TTM | USD$0 |
---|---|
Return on assets TTM | -19.13% |
Return on equity TTM | -28.96% |
Profit margin | 0% |
Book value | $3.5 |
Market capitalisation | USD$246.3 million |
TTM: trailing 12 months
There are currently 42,974 NuCana shares held short by investors – that's known as NuCana's "short interest". This figure is 57.7% down from 101,578 last month.
There are a few different ways that this level of interest in shorting NuCana shares can be evaluated.
NuCana's "short interest ratio" (SIR) is the quantity of NuCana shares currently shorted divided by the average quantity of NuCana shares traded daily (recently around 1.1 million). NuCana's SIR currently stands at 0.04. In other words for every 100,000 NuCana shares traded daily on the market, roughly 40 shares are currently held short.
However NuCana's short interest can also be evaluated against the total number of NuCana shares, or, against the total number of tradable NuCana shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NuCana's short interest could be expressed as 0% of the outstanding shares (for every 100,000 NuCana shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable NuCana shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NuCana.
Find out more about how you can short NuCana stock.
We're not expecting NuCana to pay a dividend over the next 12 months.
Over the last 12 months, NuCana's shares have ranged in value from as little as $4.04 up to $9.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NuCana's is 0.8521. This would suggest that NuCana's shares are less volatile than average (for this exchange).
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase Ib and Phase III clinical trials for the treatment of patients with biliary tract cancer; a Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trial for the treatment of patients with biliary cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.